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ORIGINAL ARTICLE
Histone deacetylase inhibitors restore IL-10 expression in lipopolysac-
charide-induced cell inflammation and reduce IL-1b and IL-6 production
in breast silicone implant in C57BL/6J wild-type murine model
Rosa Di Liddo1*, Sergio Valente2*, Samanta Taurone3, Clemens Zwergel2, Biagina Marrocco2, Rosaria Turchetta3,
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Abstract
Among epigenetic enzymes, histone deacetylases (HDACs) are responsible for regulating the
expression of an extensive array of genes by reversible deacetylation of nuclear histones as well
as a large number of non-histone proteins. Initially proposed for cancer therapy, recently the
interest for HDAC inhibitors (HDACi) as orally active, safe, and anti-inflammatory agents is rising
due to their ability in reducing the severity of inflammatory and autoimmune diseases. In
particular, selective HDAC3, HDAC6, and HDAC8 inhibitors have been described to down-
regulate the expression of pro-inflammatory cytokines (TNF-a, TGF-b, IL-1b, and IL-6). Herein,
using KB31, C2C12, and 3T3-J2 cell lines, we demonstrated that, under lipopolysaccharide-
induced in vitro inflammation, HDAC3/6/8 inhibitor MC2625 and HDAC6-selective inhibitor
MC2780 were effective at a concentration of 30 ng/mL to downregulate mRNA expression of
pro-inflammatory cytokines (IL-1b and IL-6) and to promote the transcription of IL-10 gene,
without affecting the cell viability. Afterwards, we investigated by immunohistochemistry the
activity of MC2625 and MC2780 at a concentration of 60 ng/kg animal weight to regulate
silicone-triggered immune response in C57BL/6J female mice. Our findings evidenced the
ability of such inhibitors to reduce host inflammation in silicone implants promoting a thickness
reduction of peri-implant fibrous capsule, upregulating IL-10 expression, and reducing the
production of both IL-1b and IL-6. These results underline the potential application of MC2625
and MC2780 in inflammation-related diseases.
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Introduction
Epigenetic regulation of gene expression is now recognized as
a novel approach to treat several diseases. Histone deacety-
lases (HDACs) are responsible for regulating the expression
of an extensive array of genes by catalyzing the reversible
deacetylation of "-amino groups located on the N-terminal
lysine residues of nuclear histones as well as a large number
of non-histone proteins [1,2]. Although initially used mainly
for cancer therapy, research now suggests that inhibitors of
HDAC (HDACi) could also be utilized for treating diseases
ranging from neurodegenerative [3–5] to inflammatory ones,
such as asthma and rheumatoid arthritis [6,7]. Anti-inflam-
matory properties of HDACi are interestingly observed in the
low nanomolar range, compared with the micromolar range
needed to treat cancer. The recent expanding interest in
HDAC inhibitors as orally active, safe, and anti-inflammatory
agents has been increased by the ability of these inhibitors to
reduce disease severity in several in vitro and in vivo models
of inflammatory and autoimmune diseases [6,8,9]. Histone
hyperacetylation results in up-regulation of cell-cycle inhibi-
tors (p21Cip1, p27Kip1, and p16INK4), repression of inflamma-
tory cytokines (IL-1 and IL-8), tumor necrosis factor-a (TNF-
a), and downregulation of immune stimulators (IL-6, IL-10,
and CD154) [10]. The role of HDACs in the modulation of
inflammatory mediators has been well reviewed: these
enzymes are mainly involved in the activation of T-cells
(HDAC1, HDAC6, HDAC7, and HDAC9), macrophages
(HDAC2-5, HDAC6, and HDAC7), differentiation and pro-
liferation processes (HDAC5), adhesion mechanisms of
monocytes to endothelium (HDAC3-5), and osteoclast activ-
ity (HDAC3, HDAC5, HDAC7, and HDAC8) [11]. Among
HDAC isoforms, HDAC3 is reported to play a pivotal role in
monocyte recruitment to sites of inflammation and in
macrophage cytokine production [12], while HDAC6 regu-
lates the activity of Foxp3+ T-regulatory cells [13].
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Interestingly, HDAC3-deficient macrophages stimulated with
lipopolysaccharide (LPS) demonstrated a reduced expression
of inflammatory cytokines [12]. Further studies [14] reported
that histone deacetylase isoforms regulate innate immune
response by deacetylating mitogen-activated protein kinase
phosphatase-1 and thus inhibiting Toll-like receptor (TLR)
signaling. Since their first use in aesthetic and reconstructive
mammoplasty, breast prostheses demonstrated to cause a
natural foreign body reaction (FBR) characterized by the
infiltration of inflammatory cells, including neutrophils,
monocytes/macrophages, T-cells (helper and cytotoxic sub-
types) and B-lymphocytes [15], and non-inflammatory cells,
including fibroblasts and myofibroblasts [16,17]. It is well
documented that FBR response leads to fibrotic encapsulation
around the expander in the first 20 d after surgery. In
susceptible individuals, the progression of inflammatory
reaction could promote the formation of capsule contracture,
a local complication of unknown causes [18]. The peripros-
thetic capsule represents a dynamic inflammatory reaction
that involves in early-phase monocytes/macrophages and,
later on, CD4+ T helper cells, recruited by inflammatory
microenviroment. Among cytokines released by macro-
phages, TNF-a and TGF-b stimulate neo-angiogenesis, pro-
liferation of fibroblasts, and deposition of collagenous matrix
[19]. The current knowledge suggests that the local applica-
tion of oligonucleosides targeting Connective Tissue Growth
Factor (CTGF) and TGF-b could be effective in reducing
CTGF synthesis and capsular formation. Zimman et al. [20]
detected a reduction of TGF-b1, autoantibodies against
collagen III and periprosthetic fibrosis in rats treated with
enalapril, an inhibitor of angiotensin-converting enzyme and
angiotensin II receptor antagonist. Moreover, leukotriene
receptor antagonists, such as zafirlukast and montelukast,
showed an antifibrotic activity [21,22]. In patients with
rheumatoid arthritis (RA), the co-treatment with methotrexate
and etanercept revealed to be useful to modulate T helper-1
and -2 cells and to regulate the secretion of the main
cytokines involved in the formation of fibrous capsule (IL-1,
IL-6, IL-17, TNF-a, and TGF-b) [23]. Several studies have
demonstrated that HDAC inhibitors act as modulators of the
inflammatory response: the HDAC pan-inhibitors SAHA
(Zolinza, Merck, Darmstadt, Germany) and ITF2357
(givinostat, Merck, Darmstadt, Germany) were demonstrated
to reduce the production of TNF-a, IL-1a, IL-1b, and IFN-g
from peripheral blood mononuclear cells (PBMCs) stimulated
with LPS [9,24]. The expression of inflammatory cytokines is
regulated by reversible acetylation and deacetylation of
histones and transcription factors. HDACi were demonstrated
to be effective therapeutics in animal models of rheumatoid
arthritis (RA) and have anti-inflammatory effects in RA
synovial macrophages and tissue via modulation of mRNA
stability. In particular, HDACi trichostatin A (TSA) sup-
pressed IL-6 production by RA fibroblast-like synoviocytes
stimulated with IL-1b [25]. Similarly, the treatment of LPS-
stimulated macrophages with TSA reduced IL-6, TNF-a,
and IL-1b expression [26]. In an experimental colitis model,
SAHA treatment resulted in a dose-dependent suppression of
cytokine synthesis and apoptosis induction of lamina propria
lymphocytes [27] and promoted the reduction of LPS-
induced septic shock in rodents downregulating the expres-
sion of TNF-a and IL-1b [28]. In addition, TSA suppressed
the ability of IL-1b and TNF-a to up-regulate matrix
metalloproteinase (MMP)-3, consistently with a cartilage
protective effect [29]. Moreover, ITF2357 reduced joint
inflammation in rat and mouse models, and, in contrast to
SAHA, was able to prevent joint destruction as well as
inflammation [30]. Recently, the HDAC3-selective inhibitor
MI192 was found to reduce TNF-a production and to dose
dependently suppress IL-6 production in PBMCs from RA
patients [31]. Noteworthy, the HDAC6-selective inhibitor
tubastatin A [32,13] was shown to enhance the suppressive
effects of Foxp3+ regulatory T cells (Tregs), suggesting to
be a potential therapeutic approach to slow or reverse the
pathogenesis of autoimmune disorders and prevent allograft
rejection, inflammatory bowel disease, and RA [33–35].
Recently, the specific inhibition of HDAC8 by ITF3056, an
analogue of ITF2357, was reported to downregulate both
gene expression and production of pro-inflammatory cyto-
kines [36]. Therefore, based on the findings correlating
HDACs with innate immune response, herein we investi-
gated in vitro and in vivo the anti-inflammatory activity of
two different HDAC inhibitors (MC2625 and MC2780)
selected from our own library. MC2625 (Figure 1) is an
isosteric pyridine analog of a series of aroylamminocinnamyl
hydroxamates [37–40], that carries a branched bulky group
at the cap moiety, a chemical modification previously
demonstrated to furnish isoform-selective HDAC inhibition
[41]. MC2780 (Figure 1) bears a tert-butoxycarbonylamino
group bound to the phenyl cap moiety, a structural feature
known to confer high potency and selectivity towards
HDAC6 [42]. Both MC2625 and MC2780 molecules were
tested in vitro on epithelial (KB31), fibroblast (3T3-J2), and
myogenic (C2C12) cells to evaluate their cytotoxicity by cell
viability test and their capability to modulate mRNA
expression of IL-1, IL-6, and IL-10 genes. Moreover,
histological and immunohistochemical analysis were per-
formed to study fibrous capsular reaction and pro- (IL-1b
and IL-6) and anti-inflammatory (IL-10) cytokines-mediated
immune response to silicone implants, adsorbed with
HDACi and placed in C57BL/6J female mice.
Figure 1. HDACi described as anti-
inflammatory agents. Structures of the
HDACi MC2625 and MC2780 studied in
this work.
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Materials and methods
Chemistry and biochemistry
The synthetic routes for the preparation of MC2625 (racemic
mixture) and MC2780 have been recently described by our
group [43,42]. Individual IC50 values for each HDAC isozyme
were measured with the homogeneous fluorescence-release
HDAC assay. Purified recombinant enzymes were incubated
with serial diluted inhibitors at the indicated concentration, in
10-dose IC50 mode with three-fold serial dilution starting
from 50 mM solutions. The deacetylase activities of HDACs
1–11 were measured by assaying enzyme activity using
AMC-K(Ac)GL (classes I, IIb, and IV HDACs) or
AMC-K(TFA)GL (class IIa HDACs) substrate. Deacetylated
AMC-KGL was sensitive toward lysine peptidase, and free
fluorogenic 4-methylcoumarin-7-amide (MCA) was gener-
ated, which can be excited at 355 nm and observed at 460 nm
(Reactive Biology Corp., Annapolis, MD). Data were
analyzed on a plate-to-plate basis in relationship to the
control and imported into analytical software (GraphPad
Prism, San Diego, CA).
In vitro studies of cytotoxicity and biological activity
of HDACi
Cytotoxic effects and biological activity of MC2625 and
MC2780 molecules were studied in vitro using epithelial
(KB31), fibroblast (3T3J2), and myogenic (C2C12) cell lines.
Cells were seeded (20 103 cells/cm2) in six-well tissue
culture dishes (BD Falcon, Milan, Italy) and cultured with
Dulbecco’s Modified Eagle’s Medium (DMEM low glucose,
Euroclone, Milan, Italy) supplemented with 10% fetal bovine
serum (FBS) (Sigma-Aldrich, Milan, Italy), and 1% penicillin/
streptomycin (Invitrogen, Darmstadt, Germany).
Cell viability assay
When populations reached 70% confluency, HDACi were
added to the cell cultures at different concentrations ranging
from 30 ng/mL to 300 mg/mL. After 24 h of incubation,
cytotoxicity of MC2625 and MC2780 molecules was assessed
by flow cytometry using BD Cell Viability Kit (BD
Biosciences, Milan, Italy). The detection of injured, dead,
and viable cells was performed by staining with thiazole
orange (TO), a nucleic-acid-specific dye and propidium
iodide (PI). Aliquots of 2.0 mL of TO and 1.0 mL of PI were
added to 1 mL of cell suspensions containing 5 105cells,
to obtain the final staining concentrations of 84 nM for TO
and 4.3 mM for PI. After incubation for 5 min at room
temperature, the samples were loaded on BD FACSCanto II
system (Becton Dickinson, San Jose, CA) equipped with BD
FACSDiva software. Data were acquired as a percentage of
dead, injured, and live cells discriminated using TO and PI
mean fluorescence intensity (MFI). According to the instruc-
tions of the manufacturer, high MFI value of TO combined
with negative expression of PI identified living cells, while
injured and dead cells were detected due to a decreased TO
fluorescence intensity and an intermediate or high MFI value
of PI, respectively. For analysis, MFI values of TO and PI
from HDACi-untreated samples were used as references for
each cell line. Statistical significance was calculated by
Student’s t-test comparing MC2625- and MC2780-treated
cultures to untreated cells.
Gene expression study
KB31, C2C12, and 3T3J2 cells were treated in vitro for 24 h
with MC2625 and MC2780 at concentrations of 30 ng/mL and
300 ng/mL. In order to evaluate the anti-inflammatory activity
of HDACi, we added to culture media 5 mg/mL lipopolysac-
charide (LPS) (Sigma-Aldrich, Milan, Italy). In parallel,
samples untreated (negative controls) or treated with LPS
alone (LPS-controls) were used as a reference. Total
cellular RNA was extracted using TRIzol (Invitrogen Life
Technologies, Grand Island, NY) and quantified by NanoDrop
2000 (Thermo Fisher Scientific, Inc., Waltham, MA). All
samples were reverse transcribed with Thermoscript RT-
PCR System kit (Invitrogen Life Technologies, Grand
Island, NY) and an iCycler iQ (Bio-Rad Laboratories,
Hercules, CA). The amplification reaction was carried out
using specific oligo primers (Table S1) (Invitrogen Life
Technologies, Grand Island, NY), Platinum SYBR Green
qPCR SuperMix UDG kit (Invitrogen Life Technologies,
Grand Island, NY), and a DNA Engine Opticon Real Time
Thermal Cycler (MJ Research, St. Bruno, QC, Canada). The
amount of gene products was calculated with a linear
regression analysis from standard curves, demonstrating
amplification efficiencies ranging from 95% to 100%. Data
were reported as a fold increase of target gene expression
defined as a complementary DNA (cDNA) ratio between target
gene and hypoxanthine–guanine phosphoribosyltransferase
(HPRT) housekeeping gene. Statistical significance was
calculated by Student’s t-test comparing with negative controls
(asterisk: p value 0.05) or to LPS-controls (one black
triangle: p value 0.05).
In vivo biological activity of HDACi
Ethics statement
C57BL/6J wild-type female mice (2 weeks old) (n¼ 18) were
provided by the Animal House facility of Padova University,
Italy. The use and care of animals as well as the surgical
procedures were approved and supervised by the local Ethic
committee (protocol 32132/2011 CEASA, University of
Padova, Padova, Italy). For subcutaneous implantation of
texturized silicone (Allergan, Inc., Irvine, CA), the animals
were anesthetized by isofluorane (Forane, Abbott S.P.A.,
Campoverde, Italy) (3% oxygen with the flow of 1 L/min) in a
transparent Plexiglas box. After 30 d, the animals were
sacrificed by cervical dislocation and the silicone patches
along with surrounding tissues were removed.
In vivo implantation of silicone patches adsorbed with HDACi
Round-shaped silicone implants were prepared using a 6-mm
biopsy punch (Kai Medical, Solingen, Germany) and then
sterilized at 120 C for 20 min. The patches were pre-treated
overnight at 37 C with MC2625 and MC2780 solutions
(3 mg/mL in PBS/DMSO), obtaining a final adsorbed
concentration of 60 ng/kg. HDACi-untreated silicone was
prepared and implanted as control. After a skin incision on the
back side, a patch (6 mm diameter) of texturized silicone was
DOI: 10.3109/08916934.2015.1134510 HDACi reduce silicone-triggered inflammation 3
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subcutaneously implanted in mice. After 30 d, the animals
were sacrificed by cervical dislocation and silicone along with
surrounding tissues was explanted for histological evaluation.
Histology
Explants were fixed overnight in 10% formalin solution,
washed in PBS, and embedded in paraffin (Carlo Erba
Reagents S.r.l., Milan, Italy). Sections of 4 mm thickness were
prepared (Histoslide 2000 microtome, Leica Reichert Jung,
Leica Camera Inc., Allendale, NJ) and then stained with
conventional hematoxylin–eosin (H&E) according to standard
protocols. In parallel, the analysis of capsular collagen was
performed using Trichrome Stain (Masson) Kit (Sigma-
Aldrich, Milan, Italy) according to the instructions of the
manufacturer.
Immunohistochemistry
Explants were washed in PBS, fixed in 10% formalin, and
embedded in paraffin [44]. Serial 3-mm thick sections were
cut using a rotative microtome, mounted on gelatin-coated
slides, and then processed for immunohistochemical analysis
by ABC/HRP (avidin–biotin complex/horseradish peroxidase)
technique. After deparaffinization in xylene and rehydration,
sections were immersed in citrate buffer (pH 6) and thus
subjected twice to microwave irradiation for 5 min. All
sections were treated for 30 min with 0.3% hydrogen peroxide
in methanol for quenching endogenous peroxidase activity.
Thereafter, the samples were incubated overnight at 4 C with
the following antibodies: (i) rabbit anti-IL-1b polyclonal
antibody (Santa Cruz Biotechnology, Santa Cruz, CA); (ii)
rabbit anti-IL-6 polyclonal antibody (Santa Cruz
Biotechnology, Santa Cruz, CA); (iii) rabbit anti-IL-10
polyclonal antibody (Immunological Sciences, Rome, Italy).
The immunodetection of target proteins was performed by
incubation at room temperature with secondary biotinylated
goat anti-rabbit IgG (Vector Laboratories, Burlingame, CA)
for 1 h and, at a later phase, with peroxidase-conjugated
avidin (Vectastain Elite ABC Kit Standard, Vector
Laboratories, Burlingame, CA) for 35 min. The immunoreac-
tive sites were revealed using 0.1% H2O2 and 0.05% 3,3-
diaminobenzidine (DAB) (Vector Laboratories Burlingame,
CA). Finally, sections were counterstained with Mayer’s
hematoxylin and observed using Leica DFC480 microscope
(Leica Camera Inc., Allendale, NJ). Negative control experi-
ments were carried out: (i) by omitting the primary antibody;
(ii) by substituting the primary antibody with an equivalent
amount of non-specific immunoglobulins; (iii) by pre-
incubating the primary antibody with the specific blocking
peptide (antigen/antibody¼ 5 according to supplier’s instruc-
tions). Data were collected by two experienced observers in
light microscopy. The intensity of immunoreactivity was
evaluated microdensitometrically using an IAS 2000 image
analyzer (Delta Sistemi, Rome, Italy) connected to a micro-
scope via TV camera. The calibration of system was made
taking as zero the background obtained in sections incubated
with non-immune serum. For analysis, 10 regions (100mm2
area) per section were delineated within fibrous capsule by a
measuring diaphragm and data were expressed as a fold
increase of intensity value detected for each target protein in
HDACi-treated samples compared with controls. Significant
differences were statistically defined using the analysis of
variance (ANOVA) followed by Duncan’s multiple range test
as a post hoc test.
Results
HDAC inhibition data
Both MC2625 (racemic mixture) and MC2780 molecules
were tested against all the HDAC1-11 isoforms in 10-dose
IC50 mode with three-fold serial dilution starting from 50 mM
solutions, and the relative inhibition data are recapitulated in
Table 1 [43,42]. From these data, MC2625 behaved as a
specific HDAC3/HDAC6/HDAC8 inhibitor, because it is able
to inhibit these isoforms at nanomolar (HDAC3 and HDAC6)
or submicromolar (HDAC8) concentration, while the remain-
ing HDAC enzymes are inhibited in the range 1.4–11.7 mM.
Differently, MC2780 emerged as a potent and selective
HDAC6 inhibitor, displaying an IC50 value of 0.01 mM against
this isoform and being from 120- to45000-fold less potent
versus the other HDAC enzymes.
In vitro citotoxicity study of HDACi
Epithelial KB31, fibroblast 3T3-J2, and myogenic C2C12 cell
lines were employed to assess potential citotoxic effects of
MC2625 and MC2780 molecules at concentrations ranging
from 300 mg/mL to 30 ng/mL. Based on the fluorescence
intensity values of TO and PI, flow cytometrical analysis
evidenced that 300 mg/mL MC2625 drastically affected the
viability of 3T3-J2 (0% viable cells) while exerted less
cytotoxicity in C2C12 (66% viable cells) (Figure 2). At
the same concentration, MC2780 caused 100% cell death in
3T3-J2 and C2C12 populations (Figure 3). When added at
lower doses (30 mg/mL), a higher percentage of viable cells
ranging from 85 to 96 % in 3T3-J2 cells and 90–96% in
C2C12 samples was observed, hence suggesting the suitabil-
ity of these HDACi solutions for in vitro and in vivo
evaluation of biological activity. The viability of KB31 cells
was not affected by MC2625 and MC2780 molecules, in
accordance with published data reporting that mechanisms of
resistance to HDAC inhibitors are active in tumor cells [45].
Table 1. Inhibition of HDAC1–11 isoforms by MC2625 and MC2780.
IC50 against HDAC isoforms, mM
Cpd 1 2 3 4 5 6 7 8 9 10 11
MC2625 1.42 1.77 0.08 11.7 9.37 0.01 8.77 0.61 10.6 1.8 10.2
MC2780 2.9 2.1 10.8 3.2 450 0.01 450 1.2 68.8 5.1 12.0
4 R. Di Liddo et al. Autoimmunity, Early Online: 1–11
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Evaluation of in vitro biological activity of HDACi
Originally described by its ability to inhibit T-helper (Th) 1
activation and Th1 cytokine production, interleukin 10 plays
an essential part in controlling inflammation and instructing
adaptive immune responses [46]. Besides immune cells [47],
keratinocytes [48], muscle cells [49], and fibroblasts [50]
have shown to express IL-10. Consistent with these evidences,
the analysis of qPCR products (Figure 4) evidenced a basal
expression of IL-10 in KB31, C2C12, and 3T3J2 cells
(Figure 4). As previously demonstrated for other HDAC
Figure 2. Cell viability in cell lines treated with MC2625. Cell viability test on KB31 (A), 3T3J2 (B), and C2C12 cells (C) treated with MC2625
solutions (from 300 mg/mL to 30 ng/mL) for 24 h at 37 C and measured by flow cytometry with thiazole orange (TO) and propidium iodide (PI). Data
were acquired as a percentage of dead, injured and live cells discriminated using TO and PI mean fluorescence intensity (MFI). According to
instructions of the manufacturer, high MFI value of TO combined with negative expression of PI identified living cells, while injured and dead cells
were detected due to a decreased TO fluorescence intensity and an intermediate or high MFI value of PI, respectively. For analysis, MFI values of TO
and PI from HDACi-untreated samples were used as references for each cell line. Statistical significance was calculated by Student’s t-test comparing
MC2625- and MC2780-treated cultures to untreated cells (p value50.05).
Figure 3. Cell viability in cell lines treated with MC2780. Cell viability test on KB31 (A), 3T3J2 (B), and C2C12 cells (C) exposed to MC2780
solutions (from 300 mg/mL to 30 ng/mL) for 24 h at 37 C and measured by flow cytometry with thiazole orange (TO) and propidium iodide (PI). Data
were reported as a percentage of dead, injured, and live cells measured by flow cytometry with BD Cell Viability Kit (BD Biosciences, Milan, Italy)
containing thiazole orange (TO) solution to stain all cells and propidium iodide (PI) to stain dead cells (p value50.05).
DOI: 10.3109/08916934.2015.1134510 HDACi reduce silicone-triggered inflammation 5
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inhibitors [51], MC2625 and MC2780 solutions with higher
(300 ng/mL) and lower (30 ng/mL) concentration downregu-
lated (p 0.05) the expression of IL-10 while stimulating the
transcription of IL-1b and IL-6. These data are in accordance
with other studies reporting that HDAC inhibitors deacetylate
MAPK phosphatase-1 (MKP-1) increasing TLR signaling-
mediated inflammation [52]. When the cells were cultured
with LPS alone, all samples demonstrated a significant
reduction of IL-10 transcription activity, probably due to TLR
signaling activation following MKP-1 acetylation by LPS
[52,53]. Interestingly, the co-treatment of cell cultures with
LPS and MC2780 (300 ng/mL or 30 ng/mL) or MC2625
(30 ng/mL) showed to restore (p 0.05) IL-10 gene
expression and to downregulate the transcription of pro-
inflammatory cytokines (IL-1b and IL-6). Taken into con-
sideration these in vitro findings, using an in vivo mouse
model, we, therefore, investigated the potentiality of MC2625
and MC2780 to inhibit the inflammatory process triggered by
silicone subcutaneous implantation.
In vivo anti-inflammatory activity of MC2625 and
MC2780
Round-shaped silicone implants pre-adsorbed or not with
HDACi were placed subcutaneously in 2 weeks old C57BL/6J
female mice. After 30 d from implantation, silicone patches
Figure 4. Expression of IL-1, IL-6, and IL-10 genes is modulated by MC2625 and MC2780 in LPS-mediated in vitro inflammation. KB31, C2C12,
and 3T3J2 cultures were treated in vitro for 24 h with MC2780 and MC2625 used both at 300 ng/mL and 30 ng/mL, in the presence or absence of LPS
(5mg/mL). In parallel, samples untreated (negative controls) or treated only with LPS (LPS-controls) were prepared. To prove the anti-inflammatory
activity of our HDAC inhibitors, the analysis of IL-10 gene expression was performed by qPCR. The amount of gene products was calculated using a
linear regression analysis from standard curves, demonstrating the amplification efficiencies ranging from 95% to 100%. We reported the fold increase
of gene expression that was defined as the cDNA ratio between target gene and reference gene (HPRT). Statistical significance was calculated using
Student’s t-test, comparing with negative controls (asterisk: p value50.05) or to LPS-controls (black triangle: p value50.05).
6 R. Di Liddo et al. Autoimmunity, Early Online: 1–11
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along with surrounding tissues were extracted and submitted
to histological evaluation.
The most common complications in silicone mammary
implants is the development of capsular fibrosis and capsular
contracture resulting from a silicone-mediated activation of
fibroblasts [54], macrophages, and T cells [55]. As reported
by several studies, human fibrous capsule is characterized by
three layers known as intimal, intermediate, and outer layers
where the intimal zone is the inner compartment composed of
fibrocytes and histiocytes forming an epithelial-like single
layer, synovial-type metaplasia, the intermediate layer
contains smaller fibrils in loose connective tissue, and the
outer layer is the transition zone characterized by densely
packed collagen fibers and blood vessels [56]. In response to
silicone implants, activated inflammatory cells secrete pro-
inflammatory cytokines, recruiting fibroblasts and promoting
collagen deposition. IL-1b [57] and IL-6 [58] are demon-
strated to promote the progression of inflammation and
fibrosis. In contrast, IL-10 exerts anti-inflammatory activity
and regulates collagen synthesis [59,60]. In our work, a
fibrous capsule was detected in all animals around the silicone
patch, showing a bilayered structure with cells located
predominantly in the inner layer while extracellular matrix
largely expressed in the outer layer (Figure 5). Morphometric
analysis of silicone specimens demonstrated a reduced
capsule thickness in samples treated with HDACi, suggesting
that MC2625 and MC2780 modulated in vivo the inflamma-
tory response acting on fibroblast populations and down-
regulating collagen deposition. Moreover, a significant
difference in the orientation of capsular collagen fibers was
observed among samples treated with HDAC inhibitors
compared with controls, demonstrating that MC2625 and
MC2780 differently affected the process of fibrillogenesis or
collagen assembly. The analysis by Masson’s trichrome
staining (Figure 6) evidenced that the fibers were randomly
distributed in silicone patches adsorbed with MC2625. In
contrast, controls and samples treated with MC2780 showed a
fibrotic capsule with bundled parallel fibers. The evidences
collected were consistent with the study reported by Laitung
et al. [54], who found that lower capsular formation and
contracture is related to less number of myofibroblasts in the
tissue around expanding devices. The severity of capsule
formation and contracture has a positive linear correlation
with the degree of local inflammation [18], that is largely
regulated by macrophage-derived growth factors and fibro-
cyte-stimulating cytokines, such as IL-6, TNF-a, IL-1b, and
TGF-b [61]. Compared with controls, HDACi-treated samples
showed a significant (p50.05) lower immunoreactivity for
IL-1b and IL-6 (Figure 7) besides an increased expression of
anti-inflammatory IL-10. These data were consistent with
results from our in vitro studies demonstrating that MC2625
or MC2780 would contribute to inhibit local inflammation in
silicone surrounding tissue regulating the expression of IL-1b,
IL-6, and IL-10 from inflammatory and not inflammatory
cells.
Discussion and conclusion
Histone deacetylases balance the acetylation activities of
histone acetyltransferases on chromatin remodeling and
regulate gene transcription. Accumulated evidence indicates
that HDAC activity is also associated with the development
and progression of some chronic fibrotic diseases [62]. Thus,
a growing interest is recently focused on the potential
applications of HDAC inhibitors in the treatment of disorders
arising from unbalanced fibroblast activation and prolifer-
ation. Several studies report that HDACi exerts anti-inflam-
matory effects downregulating the expression of TNF-a,
TGF-b, IL-1b, and IL-6 under in vitro and in vivo experi-
mental conditions. Moreover, it is demonstrated that HDAC
inhibitors regulate the immune response through the inhib-
ition of HDAC6 and the acetylation of non-histone proteins
(i.e., p53, GATA1-3, STAT3, STAT5, Foxp3, and NF-kB)
[63]. In our study, using in vitro and in vivo settings, two
inhibitors of HDAC, called MC2625 and MC2780, were
tested at not cytotoxic concentrations for anti-inflammatory
and anti-fibrotic activities. Both MC2625, an inhibitor
of HDAC3/6/8, and MC2780, a selective inhibitor of
Figure 6. Masson’s trichrome staining.
Histological analysis by Trichrome
(Masson) Stain on silicone patches and
surrounding tissues excised from C57BL/6J
mice. HDACi-untreated animals (+Silicone);
MC2625-treated animals (+ Silicone\+
MC2625); MC2780-treated animals
(+ Silicone\+MC2780). Cytoplasm and
muscle fibers (red (in web)/black (in print));
collagen (blue (in web)/black (in print)).
Scale bar: 10mm.
Figure 5. H&E staining. Histological analysis
by hematoxilin/eosin on silicone patches and
surrounding tissues excised from C57BL/6J
mice. HDACi-untreated animals (+Silicone);
MC2625-treated animals (+ Silicone\+
MC2625); MC2780-treated animals
(+ Silicone\+MC2780). Capsule thickness
was marked by square brackets. Scale bar:
25mm.
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HDAC6, demonstrated comparable anti-inflammatory effects
downregulating IL-1b, IL-6, and stimulating the expression of
IL-10 but diverged in the anti-fibrotic abilities. The differen-
tial biological response to MC2625 and MC2780 well
correlated with their distinct inhibition profile and were
consistent with published evidences reporting the ability of
HDACi to regulate the innate immune response inhibiting
inflammatory cells and stimulating conventional and regula-
tory T lymphocytes [64]. It is reported that the inhibition of
HDAC6 is essential for the stabilization of Foxp3, the
winged-helix family transcription factor involved in the
differentiation of Treg cells from CD4+ naı¨ve T cells.
Taken into consideration that IL-10 is expressed by Treg
and IL-10 suppresses the production of pro-inflammatory
cytokines by dendritic cells and macrophages [65], the
comparable anti-inflammatory activity of MC2625 and
MC2780 could be dependent on the inhibition that both
molecules exerted on HDAC6. The reduction of fibrous
capsule thickness observed in mice treated with HDAC
inhibitors further confirmed the ability of both MC2625 and
MC2780 to modulate the inflammatory response, although
with a different grade. The implantation of biomaterials is
Figure 7. Silicone implantation-induced inflammation is reduced in vivo by MC2625 and MC2780. Immunohistochemical analysis of IL-1, IL-6, and
IL-10 genes in explants from mice transplanted with silicone alone (group: + Silicone), silicone adsorbed with MC2625 (group: + Silicone\+ MC2625)
or MC2780 (group: + Silicone\+ MC2780). Immunoreactive sites (brown) were revealed by exposure to DAB substrate. The intensity of
immunoreactivity was evaluated microdensitometrically using an IAS 2000 image analyzer (Delta Sistemi, Rome, Italy) connected to microscope via
TV camera. The calibration of system was made taking as zero the background obtained in sections incubated with non-immune serum. For analysis,
ten regions (100mm2 area) per section were delineated within fibrous capsule (black asterisk) by a measuring diaphragm. In histograms, data were
expressed as a fold increase of intensity value detected for each target protein in HDACi-treated samples compared to controls. Significant differences
were statistically defined using the analysis of variance (ANOVA) followed by Duncan’s multiple range test as a post hoc test (black circle:
p value50.05).
8 R. Di Liddo et al. Autoimmunity, Early Online: 1–11
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known to trigger a classical foreign body response and leads
to a chronic inflammation [66] driven by monocytes and
macrophages recruited by chemokines and chemo attract-
ants such as transforming growth factor-b (TGF-b), platelet-
derived growth factor (PDGF), and interleukin (IL-1). After
chronic inflammation is resolved, fibroblast cells activate
and differentiate into myofibroblasts due to the stimulation
of TGF-b, a key regulator of extracellular matrix formation
and remodeling [67]. Fibroblasts and myofibroblasts secrete
collagen types I and III to form a fibrous capsule around
the implant and contract the wound edges. Several studies
demonstrated that TGF-b-inducible genes, including colla-
gen and smooth muscle actin are suppressed by HDAC
inhibitors [68,69] and the extracellular matrix remodeling is
regulated by the inhibition of class I HDAC3 [70]
Moreover, also the process of collagen assembly or
fibrillogenesis has been demonstrated to be affected by
HDAC inhibitors [71]. In our study, although both HDAC
inhibitors promoted a reduction of fibrous capsular thick-
ness, only MC2625 showed to exert an anti-fibrotic activity
interfering with the parallel assembly of collagen, a
predisposing condition to the development of capsular
contracture. Consistent with data above reported, this
biological effect was hypothesized to be mediated by the
inhibition of class I HDAC3 and 8.
Further studies on MC2625 and MC2780 will explore their
potential therapeutical applications in other inflammation-
related diseases especially those well responding to the
administration of recombinant IL-10 [72].
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